(CercleFinance.com) – Are investors reserving an apparently lukewarm reception to the announcement of the approval of its Covid vaccine since Novavax only takes + 2.3%?
But that would be forgetting the + 16% taken at the opening ($ 241, filling the ‘gap’ of $ 233.8 on 09/27) with a peak of $ 243 a few minutes later (while the S & P500 lost -1 , 6%).
Over a week, the title takes + 27% (in the morning, it was + 40%).
Beyond $ 243, Novavax could try to return to the zenith of $ 2,667.7 on 09/08.
Copyright © 2021 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute decision support for investors. Cercle Finance cannot be held liable directly or indirectly following the use of information and analyzes by readers. It is recommended that anyone who is not informed to consult a professional adviser before any investment. This indicative information in no way constitutes an invitation to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
